Search

Your search keyword '"Ibáñez, Laura"' showing total 3 results
Start Over Author "Ibáñez, Laura" Topic drug resistance
3 results on '"Ibáñez, Laura"'

1. Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing

Author

Pou, Christian, Noguera-Julian, Marc, Pérez-Álvarez, Susana, García, Federico, Delgado, Rafael, Dalmau, David, Álvarez-Tejado, Miguel, Gonzalez, Dimitri, Sayada, Chalom, Chueca, Natalia, Pulido, Federico, Ibáñez, Laura, Rodríguez, Cristina, Casadellà, Maria, Santos, José R., Ruiz, Lidia, Clotet, Bonaventura, and Paredes, Roger

Published
2014
Full Text
View/download PDF

2. Monitoring HIV Viral Load in Resource Limited Settings: Still a Matter of Debate?

Author

Arnedo, Mireia, Alonso, Elena, Eisenberg, Nell, Ibáñez, Laura, Ferreyra, Cecilia, Jaén, Angels, Flevaud, Laurence, Khamadi, Samuel, Roddy, Paul, Gatell, Jose Maria, and Dalmau, David

Subjects
HIV infections, THERAPEUTICS, DRUG resistance, GENETIC mutation, HIGHLY active antiretroviral therapy
Abstract

Introduction: Consequences of lack of viral monitoring in predicting the effects of development of HIV drug resistance mutations during HAART in resource-limited settings (RLS) is still a matter of debate. Design: To assess, among HIV+ patients receiving their first-line HAART, prevalence of virological failure and genotypic resistance mutations pattern in a Médécins Sans Frontières/Ministry of Health programme in Busia District (Kenya). Methods: Patients with HAART treatment for ⩾12 months were eligible for the study and those with HIV-RNA ⩾5000 copies/ml underwent genotypic study. Total HIV-1 RNA from Dried Blood Spots was extracted using Nuclisens method. Results: 926 patients were included. Among 274 (29.6%) patients with detectable viral load, 55 (5.9%) experienced treatment failure (viral load >5.000 copies/ml); 61.8% were female and 10 (18.2%) had clinical failure. Median CD4 cell count was 116 cell/mm3 (IQR: 54-189). Median HIV-RNA was 32,000 copies/ml (IQR: 11000-68000). Eighteen out of 55 (33%) samples could be sequenced on PR and RT genes, with resistance associated mutations (RAMs) in 15 out of 18 samples (83%). Among patients carrying RAMs, 12/15 (81%) harboured RAMs associated to thymidine analogues (TAMs). All of them (100%) showed M184V resistance associated mutation to lamivudine as well as NNRTI's RAMS. Conclusions: Virological failure rate in resource-limited settings are similar to those observed in developed countries. Resistance mutation patterns were concordant with HAART received by failing patients. Long term detectable viral load confers greater probability of developing resistance and as a consequence, making difficult to find out a cost-effective subsequent treatment regimen. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

3. Monitoring HIV viral load in resource limited settings: still a matter of debate?

Author

Arnedo, Mireia, Alonso, Elena, Eisenberg, Nell, Ibáñez, Laura, Ferreyra, Cecilia, Jaén, Angels, Flevaud, Laurence, Khamadi, Samuel, Roddy, Paul, Gatell, José M., Dalmau, David, Busia OR Study Group, and Universitat de Barcelona

Subjects
Male, Non-Clinical Medicine, Epidemiology, Human immunodeficiency virus (HIV), lcsh:Medicine, HIV Infections, Drug resistance, medicine.disease_cause, Global Health, Antiretroviral Therapy, Highly Active, Genotype, HIV Seropositivity, lcsh:Science, Health Systems Strengthening, Multidisciplinary, Lamivudine, Antiretrovirals, HIV diagnosis and management, Middle Aged, Viral Load, Resistance mutation, Treatment Outcome, HIV epidemiology, Medicine, Infectious diseases, Female, Viral load, HIV drug resistance, medicine.drug, Research Article, Adult, medicine.medical_specialty, Adolescent, Clinical Research Design, Anti-HIV Agents, Viral diseases, Microbiology, Medication Adherence, Immune Deficiency, Internal medicine, Virology, medicine, VIH (Virus), Humans, Genotyping, Biology, Aged, Resistència als medicaments, Health Care Policy, business.industry, HIV (Viruses), lcsh:R, Immunity, HIV, Kenya, Antiretroviral agents, CD4 Lymphocyte Count, Cross-Sectional Studies, lcsh:Q, Clinical Immunology, Health Statistics, business
Abstract

INTRODUCTION: Consequences of lack of viral monitoring in predicting the effects of development of HIV drug resistance mutations during HAART in resource-limited settings (RLS) is still a matter of debate. DESIGN: To assess, among HIV+ patients receiving their first-line HAART, prevalence of virological failure and genotypic resistance mutations pattern in a Médécins Sans Frontières/Ministry of Health programme in Busia District (Kenya). METHODS: Patients with HAART treatment for ≥12 months were eligible for the study and those with HIV-RNA ≥5000 copies/ml underwent genotypic study. Total HIV-1 RNA from Dried Blood Spots was extracted using Nuclisens method. RESULTS: 926 patients were included. Among 274 (29.6%) patients with detectable viral load, 55 (5.9%) experienced treatment failure (viral load >5.000 copies/ml); 61.8% were female and 10 (18.2%) had clinical failure. Median CD4 cell count was 116 cell/mm3 (IQR: 54-189). Median HIV-RNA was 32,000 copies/ml (IQR: 11000-68000). Eighteen out of 55 (33%) samples could be sequenced on PR and RT genes, with resistance associated mutations (RAMs) in 15 out of 18 samples (83%). Among patients carrying RAMs, 12/15 (81%) harboured RAMs associated to thymidine analogues (TAMs). All of them (100%) showed M184V resistance associated mutation to lamivudine as well as NNRTI's RAMS. CONCLUSIONS: Virological failure rate in resource-limited settings are similar to those observed in developed countries. Resistance mutation patterns were concordant with HAART received by failing patients. Long term detectable viral load confers greater probability of developing resistance and as a consequence, making difficult to find out a cost-effective subsequent treatment regimen.

Catalog

Books, media, physical & digital resources
See catalog results